Affiliated with a Castle Connolly Top Hospital
Who is Dr. Weng, Hematology / Oncology Specialist in Stanford, CA?
Dr. Wen-Kai Weng, MD, PHD is a Hematology / Oncology Specialist, who primarily practices in Stanford, CA with 1 additional practice location. He is board certified by the American Board of Internal Medicine. Dr. Weng graduated from Chungshan Medical College and completed his residency at University of Texas Medical School. Dr. Weng is fluent in English and Chinese, and is currently seeing new patients. Dr. Weng’s practice accepts Kaiser Permanente, Medicaid, Medicare, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Weng’s office at (650) 723-7689.
Where did Dr. Weng go to medical school and complete their residency?
Fellowship: Stanford University School of Medicine,Stanford, Ca, United States
Residency: University of Texas Medical School
Medical School: Chungshan Medical College
Is Dr. Weng board certified in Hematology / Oncology Specialist?
Yes, Dr. Wen-Kai Weng, MD, PHD is board certified by the American Board of Internal Medicine , American Board of Internal Medicine since 2007
What languages does Dr. Weng speak?
Dr. Weng and their clinical team can communicate with patients in the following languages:
Chinese
English
What conditions does Dr. Weng treat?
As a Hematology / Oncology Specialist, Dr. Weng diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Weng. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.
Also known as:
- Diffuse Large B-cell Lymphoma
- Mantle Cell Lymphoma
- Peripheral T-Cell Lymphoma
- Mycosis Fungoides
- Mature T/NK-cell Lymphoma
- Cutaneous T-cell Lymphoma
- Non-Hodgkin Lymphoma
- Anaplastic Large Cell Lymphoma, ALK-Negative
- Lymphoma
- Mycosis fungoides
- DLBCL
- Aggressive B-cell Lymphoma
- Diffuse B-cell Lymphoma
- MCL
- Mantle Cell Lymphoma Cancer
- Lymphatic Cancer
- Malignant Lymphoma
- Cutaneous T-cell lymphoma
- CTCL
- Alibert-Bazin syndrome
- T-cell Lymphoma
- NK-cell Lymphoma
- Peripheral T-cell Lymphoma
- Skin T-cell lymphoma
- Lymphosarcoma
- NHL
ICD-10 Codes:
- C8330: Diffuse large B-cell lymphoma, unspecified site
- C8310: Mantle cell lymphoma, unspecified site
- C8440: Peripheral T-cell lymphoma, not elsewhere classified, unspecified site
- C8400: Mycosis fungoides, unspecified site
- C8490: Mature T/NK-cell lymphomas, unspecified, unspecified site
- C84A0: Cutaneous T-cell lymphoma, unspecified, unspecified site
- C8449: Peripheral T-cell lymphoma, not elsewhere classified, extranodal and solid organ sites
- C8590: Non-Hodgkin lymphoma, unspecified, unspecified site
- C8470: Anaplastic large cell lymphoma, ALK-negative, unspecified site
Also known as:
- Acute Myeloid Leukemia in Remission
- Acute Lymphocytic Leukemia in Remission
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Acute Lymphocytic Leukemia
- AML Leukemia in Remission
- Acute Myeloblastic Leukemia in Remission
- Acute Myelogenous Leukemia in Remission
- ALL Leukemia in Remission
- Acute Lymphoblastic Leukemia in Remission
- Childhood Leukemia in Remission
- AML Leukemia
- Acute Myeloblastic Leukemia
- Acute Myelogenous Leukemia
- ALL
- Acute lymphocytic leukemia
- Lymphoblastic leukemia
ICD-10 Codes:
- C9201: Acute myeloblastic leukemia, in remission
- C9101: Acute lymphoblastic leukemia, in remission
- C9200: Acute myeloblastic leukemia, not having achieved remission
- C9100: Acute lymphoblastic leukemia not having achieved remission
Also known as:
- Multiple Myeloma
- Multiple Myeloma in Remission
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ)
- Active multiple myeloma
- Untreated multiple myeloma
- Plasma cell myeloma
- Plasma Cell Myeloma in Remission', 'Kahler's Disease in Remission
- Myeloma in Remission
ICD-10 Codes:
- C9000: Multiple myeloma not having achieved remission
- C9001: Multiple myeloma in remission
Also known as:
- Bone Marrow Transplant
- Bone Marrow Transplantation
- Stem Cell Transplant
- Hematopoietic Stem Cell Transplant
- Marrow Transplant
ICD-10 Codes:
- Z9481: Bone marrow transplant status
Also known as:
- Myelodysplastic Syndrome
- Myelodysplastic Syndromes
- Myelodysplastic Syndromes Treatment (PDQ®)
- MDS
- Preleukemia
- Bone marrow failure disorder
ICD-10 Codes:
- D469: Myelodysplastic syndrome, unspecified
Also known as:
- Stem Cell Donation
- Stem Cells
- Donate stem cells
- Bone marrow donation
- Hematopoietic stem cell donation
ICD-10 Codes:
- Z52001: Unspecified donor, stem cells
Also known as:
- Hodgkin Lymphoma
- Hodgkin's Disease', 'Hodgkin's Lymphoma
ICD-10 Codes:
- C8190: Hodgkin lymphoma, unspecified, unspecified site
Which procedures does Dr. Weng perform as a Hematology / Oncology Specialist?
As a Hematology / Oncology Specialist, procedures performed by a Dr. Wen-Kai Weng may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
For detailed information, please contact Dr. Weng's office.
Does Dr. Weng accept my insurance?
Dr. Weng accepts most major insurance plans. Important: Please call our office at (650) 723-7689 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Weng accept in Stanford, CA?
Dr. Weng in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Central California Alliance for Health
CVS Health (formerly Aetna)
Kaiser Permanente
Medicaid
Medicare
OptumRx
UnitedHealthcare
Valley Health Plan
View All Insurances
Where is Dr. Weng's office located?
Recognitions
Publications
Targeting CD137 enhances the efficacy of cetuximab.
jourl of clinical investigation, 2014
Minimal residual disease monitoring with high
SCIENCE TRANSLATIOL MEDICINE, 2013
The histone deacetylase inhibitor, romidepsin
AMERICAN JOURL OF HEMATOLOGY, 2012
Stimulation of tural killer cells with a CD137
JOURL OF CLINICAL INVESTIGATION, 2012
The IgG Fc Receptor Fc?RIIIa 158 V
JOURL OF CLINICAL ONCOLOGY, 2010
Tumor-specific recombint idiotype immunisation after chemotherapy as initial treatment for
LEUKEMIA & LYMPHOMA, 2009
Immune-mediated antitumor effects with antibody therapy.
American Society of Clinical Oncology Educatiol Book, 2005
Clinical outcome of lymphoma patients after idiotype vaccition is correlated with humoral immune
JOUNRAL OF CLINICAL ONCOLOGY, 2004
Two immunoglobulin G fragment C receptor polymorphisms independently predict response
JOURL OF CLINICAL ONCOLOGY, 2003
Differential induction of D-binding activities following CD19 cross
JOURL OF IMMUNOLOGY, 1997
SIGLING THROUGH CD19 ACTIVATES VAV MITOGEN-ACTIVATED PROTEIN
JOURL OF BIOLOGICAL CHEMISTRY, 1994
FUNCTIOL EFFECT OF IL-7-ENHANCED CD19 EXPRESSION ON HUMAN B-CELL PRECURSORS
JOURL OF IMMUNOLOGY, 1993
Targeting CD137 enhances the efficacy of cetuximab.
journal of clinical investigation, 2014
Total lymphoid irradiation-antithymocyte globulin conditioning
Biology of blood and marrow transplantation, 2014
Minimal residual disease monitoring with high
SCIENCE TRANSLATIONAL MEDICINE, 2013
Cancer Vaccines and T Cell Therapy
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013
Prophylactic rituximab after allogeneic transplantation decreases B
BLOOD, 2012
The histone deacetylase inhibitor, romidepsin
AMERICAN JOURNAL OF HEMATOLOGY, 2012
Tandem chemo-mobilization followed by high
BONE MARROW TRANSPLANTATION, 2012
Stimulation of natural killer cells with a CD137
JOURNAL OF CLINICAL INVESTIGATION, 2012
Transcriptome sequencing in Sezary syndrome identifies Sezary cell
BLOOD, 2012
Adoptive Immunotherapy with Cytokine
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011
Phase I/II Trial of GN-BVC
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010
The IgG Fc Receptor Fc?RIIIa 158 V
JOURNAL OF CLINICAL ONCOLOGY, 2010
TLI and ATG conditioning with low risk of graft-versus
BLOOD, 2009
Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not
LEUKEMIA & LYMPHOMA, 2009
Immunoglobulin G Fc Receptor Polymorphisms Do Not Correlate with Response to Chemotherapy or
LEUKEMIA & LYMPHOMA, 2009
Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for
LEUKEMIA & LYMPHOMA, 2009
A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following
CLINICAL CANCER RESEARCH, 2008
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122
BLOOD, 2008
Humoral immune response
BLOOD, 2007
Immune-mediated antitumor effects with antibody therapy.
American Society of Clinical Oncology Educational Book, 2005
Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune
JOUNRAL OF CLINICAL ONCOLOGY, 2004
Two immunoglobulin G fragment C receptor polymorphisms independently predict response
JOURNAL OF CLINICAL ONCOLOGY, 2003
Hepatitis C virus (HCV) and lymphomagenesis
LEUKEMIA & LYMPHOMA, 2003
Expression of complement inhibitors CD46, CD55
BLOOD, 2001
Differential induction of DNA-binding activities following CD19 cross
JOURNAL OF IMMUNOLOGY, 1997
SIGNALING THROUGH CD19 ACTIVATES VAV MITOGEN-ACTIVATED PROTEIN
JOURNAL OF BIOLOGICAL CHEMISTRY, 1994
FUNCTIONAL EFFECT OF IL-7-ENHANCED CD19 EXPRESSION ON HUMAN B-CELL PRECURSORS
JOURNAL OF IMMUNOLOGY, 1993
What is Dr. Weng's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Weng's National Provider Identifier (NPI) number is 1659428241.
What common questions do patients ask about Dr. Weng?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Weng
What is Dr. Wen-Kai Weng's specialty?
Dr. Weng is a Hematology / Oncology Specialist near Stanford, CA. An internist doctor of osteopathy specializing in the combined treatment of hematology and oncology disorders. A doctor of osteopathy who is board eligible or certified by the American Osteopathic Board of Internal Medicine was previously able to obtain a Certificate of Special Qualifications in Hematology and Oncology; however, this certificate is no longer available. Contact Dr. Weng to book an appointment today.
Is this Dr. Wen-Kai Weng affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Weng is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
Where can I learn more about Hematology / Oncology Specialist?
Explore Hematology / Oncology Specialist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Wen-Kai Weng accepting new patients in Stanford, CA?
Yes, Dr. Wen-Kai Weng is accepting new patients at this time.
Does Dr. Wen-Kai Weng offer online booking?
Please contact Dr. Weng's office at (650) 723-7689 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Wen-Kai Weng?
Please contact Dr. Weng's office at (650) 723-7689 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Wen-Kai Weng have?
Dr. Wen-Kai Weng is certified by the American Board of Internal Medicine.
Other Hematology / Oncology Specialist Near Stanford, CA
Hematologist
Accepting patientsMedical Oncologist
Accepting patientsMedical Oncologist
Accepting patients